June 7, 2018 08:46 AM EDT

That big Biogen deal you were waiting for? Keep waiting

John Carroll

Editor & Founder

Still waiting for that big Biogen $BIIB pact?

This isn’t it.

Biogen has journeyed to Tokyo for its latest drug deal, picking up an option on a thrombolytic agent that could protect acute ischemic stroke patients. Biogen is paying $4 million upfront to bag the option from TMS, led by Professor Keiji Hasumi’s team of scientists from Tokyo Univesity of Agriculture and Technology. If they pick up the option, it will cost Biogen another $18 million, with a $335 million package of milestones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

That big Biogen deal you were waiting for? Keep waiting

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Senators want to know more on why Novo is discontinuing its insulin Levemir

That big Bio­gen deal you were wait­ing for? Keep wait­ing

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

That big Biogen deal you were waiting for? Keep waiting

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Senators want to know more on why Novo is discontinuing its insulin Levemir